secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115933
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023
--------------------------------------------------------------------------------

- Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.
- Cash and securities $267.4M as of Sep 30; expected to fund operations through end of 2024.
- Phase 3 VERIFY enrollment completion expected H2 2023 due to site staff shortages.
- Appointed Arturo Molina, M.D., M.S. as CMO, prioritizing rusfertide program.
- De-prioritized PN-943; no further internal resources; seeking out-licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/0001104659-22-115933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/tm2229956d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer